Unilens Vision Inc. Declares Regular Quarterly Cash Dividend of U.S. $0.09...(se describedin the forward- looking stat...),Health
Navigation Links
Unilens Vision Inc. Declares Regular Quarterly Cash Dividend of U.S. $0.09 Per Share
Date:2/1/2008
se described in the forward- looking statements, please refer to the Company's most recent filings with the SEC and the TSX Venture Exchange. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
For more information, please contact:
Leonard Barker CFO, Unilens Vision Inc. at (727) 544-2531
'/>"/>
| SOURCE Unilens Vision Inc. Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. Unilens Vision Reports Record First Quarter Earnings and Royalty Income
2. Unilens Names Eschenbach Optik Exclusive Worldwide Distributor of the UniVision(R) Low Vision Lens
3. Blue Cross Blue Shield of Michigan Says Guaranteed Access Provisions of Insurance Reform Bills Protect Michigan Consumers Twice-Over
4. Crdentia Appoints Charlie Mayhone to Director of Operations for its National Travel Division and Charlotte, North Carolina Market
5. NovaVision to be Featured at 2008 Florida Venture Capital Conference
6. LCA-Vision Announces Upcoming Investment Community Events
7. Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross and Lifetime Television Deliver 20 Million Online Petition Signatures to Capitol Hill to Urge Congress to Stop Drive-Through Mastectomies
8. Cell division studies hint at future cancer therapy
9. Contact lenses with circuits, lights a possible platform for superhuman vision
10. Technique enhances digital television viewing for visually-impaired
11. University Hospitals Case Medical Center Ophthalmology gets grant for vision-threatening conditions
Post Your Comments:
(Date:12/2/2008)...oducts, home to sodium, study says , , ...lenty of sodium -- commonly known as salt -- in fo...should know that lower-fat foods can have much mor...inding of a report published online Monday by Con... 37 common supermarket items and found large amoun...
(Date:12/2/2008)...eld biopharmaceutical company, today announced tha...nvestigational product candidate, HZT 501, met all... fixed-dose combination product containing ibuprof...gnificant reduction in the incidence of non-steroi...astrointestinal (gastric and/or duodenal) ulcers i...
(Date:12/2/2008)...roPhage, Inc., http://www.microphage.com , annou...e company,s Board of Directors. Taussig was presi...rch Center in Denver, the nation,s leading institu... to 2006. His medical specialty,is pediatric pul...ensively and am impressed with its progress,in de...
(Date:12/2/2008)...-- In the wake of the deaths of two persons in pub...ern of abuse and neglect of those who have psychia...ndividuals is calling on the incoming Obama admini...als to institute widespread, substantive reforms i...would include raising standards and regulatory exp...
Breaking Medicine News(10 mins):Health News:High Salt Levels Common in Many Foods 2Health News:Horizon Therapeutics announces 2 pivotal HZT-501 Phase 3 trials meet primary endpoints 2Health News:MicroPhage Selects Lynn Taussig, MD for Board of Directors 2Health News:Tragedies Underscore Crisis in U.S. Public Mental Health System: National Advocacy Organization Demands Reforms 2Health News:Tragedies Underscore Crisis in U.S. Public Mental Health System: National Advocacy Organization Demands Reforms 3[0] High Salt Levels Common in Many Foods[0] Horizon Therapeutics announces 2 pivotal HZT-501 Phase 3 trials meet primary endpoints[0] MicroPhage Selects Lynn Taussig, MD for Board of Directors[0] Tragedies Underscore Crisis in U.S. Public Mental Health System: National Advocacy Organization Demands Reforms
...ngh set up a task force to fill up the healthcare ... lab technicians. The recruitment not only fills /...unemployed. The move is based on the recommendati...onal Commission on Macroeconomics and Health, high...
...d the lives of two children in Mumbai and many mor...ed at various hospitals. // Health authorities sai...to treat those 90-odd people who are undergoing tr... to hospitals Wednesday, particularly in south Mum...
...proved that decrease in the fine particulate air p...pulation. This drop in mortality rates was specifi...ory disease, according to Dr. Francine Laden, from...lained in a statement. Several epidemiologic studi...
...higher in the opinion of parents’ when compared to...as new research has pointed out that Australian Fo...ed to all other types of football. // The Aussie ...ports injuries, the second place being occupied by...
Other Medicine News:(Date:11/28/2008)...ember 28 German biotech company,P...lized HIV monitoring and,AIDS patient follow-up d...In,the year 2008, 2.5 million patient tests have ...ly affordable "CyFlow" system, supporting already,...Due to introduction of the,Partec innovation, the...
(Date:11/26/2008)...ity, automation and intelligent clinical applicati...ll new level , , CHICAGO, Ill., Nov. 26 /PR...w.siemens.com/healthcare ) highlights the ACUSON ...), the world,s first multi-use, automated volume ...ssembly and Annual Meeting of the Radiological Soc...
(Date:11/25/2008)...dents against expanding statin use broadly in wake....J., Nov. 25 JUPITER, a clinical t...ascular risk of healthy patients with elevated CRP...adults, according to a national poll directed at h...part in the online poll conducted by medical news ...
(Date:11/25/2008)...linical Trial to Assess Survival of Patients Recei...resectable Hepatocellular Carcinoma , , BEL...es Oncology, Inc. (LSO) today announced the comple...ial of Light Infusion Therapy(TM) (Litx(TM)) as a ...a (HCC), also known as hepatoma or primary liver c...
Breaking Medicine Technology:German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2Siemens Introduces New Standard of Care for Breast Ultrasound 2Siemens Introduces New Standard of Care for Breast Ultrasound 3Siemens Introduces New Standard of Care for Breast Ultrasound 4Siemens Introduces New Standard of Care for Breast Ultrasound 5Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Citizens Republic Bancorp Selects HealthPlus as Sole Provider of Health Insurance for 2009 30619 1Citizens Republic Bancorp Selects HealthPlus as Sole Provider of Health Insurance for 2009 30619 2Travis E Baugh Named President COO of HEALTHPOINT Ltd 30614 1Travis E Baugh Named President COO of HEALTHPOINT Ltd 30614 2Protein folding researcher David Baker to receive Sackler Prize in Biophysics 6038 1Protein folding researcher David Baker to receive Sackler Prize in Biophysics 6038 2Huntington Area Development Council Attracts Technology Based Startup Companies With 24150 000 Grant From Verizon West Virginia 9358 1Huntington Area Development Council Attracts Technology Based Startup Companies With 24150 000 Grant From Verizon West Virginia 9358 2[0] German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008[0] Siemens Introduces New Standard of Care for Breast Ultrasound[1] Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows[0] Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma
...h 12, 2007--Inflazyme,Pharmaceuticals Ltd. (TSX: I...nary results of the Phase 2b CAPSICS study with,IP...nce between,patients who received drug or placebo....rge and consistent across a number of,the end-poin... its,external experts to determine if anything unt...
...r BLA filing for C1-inhibitor,replacement therapy,...- Lev,Pharmaceuticals, Inc. (Lev) today announced ...rial of C1-esterase inhibitor (C1-INH),for the acu...e,acute study, which is part of the company,s CHAN...anofiltration Generation,evaluating Efficacy), the...
Other Medicine Technology:Inflazyme Announces Outcome of Review of Phase 2b Asthma Study:,Potential Mitigating Factors Identified which Prevent Clear,Interpretation of Results 2Inflazyme Announces Outcome of Review of Phase 2b Asthma Study:,Potential Mitigating Factors Identified which Prevent Clear,Interpretation of Results 3Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 2Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 3Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 4Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 5...feature-packed projectors ideal for any practice. ...for longer life -- up to 2,000 hours under typical...tial cost with an incandescent illumination system.... And both provide exceptionally even illumination...
...cal design and utilizes a multi-layered, multi-coa... producing a measurable 20% increase in optical re...lity of the Ultra Series also results in a 20% inc...of view and a 14% increase in depth of field. A si...
With the touch of a button, the Marco Encore Automatic Chair quickly reclines from an upright position to a fully horizontal, flat-table mode-or anywhere in between.
Both the Marco Keratometer I and Keratometer II are one position instruments for objectively measuring corneal curvature. The keratometer II has the added feature of internal readings for the presbyo
Medicine Products:| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |